Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P00326
UPID:
ADH1G_HUMAN
Alternative names:
Alcohol dehydrogenase subunit gamma
Alternative UPACC:
P00326; Q4PJ18; Q5WRV0; Q6LBW4; Q6NWV0; Q6NZA7
Background:
Alcohol dehydrogenase 1C, also known as Alcohol dehydrogenase subunit gamma, is pivotal in ethanol catabolism, showcasing high activity for ethanol oxidation. This enzyme's efficiency in breaking down ethanol underscores its critical role in metabolic processes.
Therapeutic significance:
Understanding the role of Alcohol dehydrogenase 1C could open doors to potential therapeutic strategies. Its central function in ethanol metabolism suggests its potential impact on conditions related to alcohol consumption.